Westchester Capital Management (New York)’s Apellis Pharmaceuticals APLS Stock Holding History

Westchester Capital Management (New York)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-227,489	Closed	-$9.15M	–	312
2026 Q1	$9.15M	Buy	+227,489	New	+$4.9M	0.41%	49

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Westchester Capital Management (New York)'s APLS Position: Q2 2026 in Review

Westchester Capital Management (New York) sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 227,489 shares — an estimated $9.15M sold.

Westchester Capital Management (New York) first reported a position in APLS in Q1 2026 and held it in 1 quarter. The position peaked at $9.15M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Westchester Capital Management (New York) reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Westchester Capital Management (New York) sold 227,489 Apellis Pharmaceuticals shares in Q2 2026, an estimated $9.15M.
Westchester Capital Management (New York) first reported a position in Apellis Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Westchester Capital Management (New York)'s Apellis Pharmaceuticals position peaked at $9.15M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Westchester Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.